Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 482-140-6 | CAS number: 13641-96-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 26 Mar - 27 Jul 2010
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study with acceptable restrictions
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 010
- Report date:
- 2010
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- other: Guidelines for the testing of chemicals section 4: Health effects (ministry of environmental protection of people's republic of china)
- Deviations:
- no
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 408 (Repeated Dose 90-Day Oral Toxicity Study in Rodents)
- Version / remarks:
- adopted in 2018
- Deviations:
- yes
- Remarks:
- There are major deviations from the current OECD guideline. For details, please refer to "Princip les of method if other than guideline".
- Principles of method if other than guideline:
- Deviations from the current OECD 408 guideline included the following:
stability of test substance in vehicle not shown, justification for choice of vehicle not given, achieved concentration, stability and homogeneity of the test substance formulation not analysed, no detailed clinical observation, no ophthalmological changes and sensory reactivity examined, no individual animal data provided, haematocrit, HDL, LDL and thyroid parameters in the blood not measured, epididymides, prostate, uterus, pituitary gland and thyroid not weighed, histopathology not performed on pituitary gland, eye, salivary glands, oesophagus, parathyroid, aorta, trachea, cervix, mammary gland, vagina, skeletal muscle, bone and skin, no historical control data provided and not GLP. - GLP compliance:
- no
- Remarks:
- The study was performed to meet the requirements of a non-EU Regulatory Authority. A quality assurance statement was included.
- Limit test:
- no
Test material
- Reference substance name:
- -
- EC Number:
- 482-140-6
- EC Name:
- -
- Cas Number:
- 13641-96-8
- Molecular formula:
- Hill formula: C6 H7 N O3 CAS formula: C6 H7 N O3
- IUPAC Name:
- 2-isocyanatoethyl prop-2-enoate
- Test material form:
- liquid
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Shanghai SLAC Laboratory Animal Co., Ltd., China
- Females (if applicable) nulliparous and non-pregnant: not specified
- Weight at study initiation: 110 - 140 g (males and females)
- Housing: Two animals were housed in one polycarbonate cage.
- Diet: fed with powdered animal diet (Suzhou Shuangshi Laboratory Animal Feed Co., Ltd.), ad libitum
- Water: sterilized water, ad libitum
- Acclimation period: 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20 - 25
- Humidity (%): 40 - 70
- Photoperiod (hrs dark / hrs light): 12/12
IN-LIFE DATES: From: 09 May 2010 To: 28 Jun 2010
Administration / exposure
- Route of administration:
- oral: gavage
- Details on route of administration:
- The test substance was administered orally to animals once daily by a metallic stomach catheter for 90 days. The administered dose volume, 5 mL/kg bw, was calculated on the basis of individual body weight at the beginning of each week.
- Vehicle:
- corn oil
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:
Prescribed amount of test substance was weighed and diluted with corn oil to the correct concentrations.
VEHICLE
- Justification for use and choice of vehicle: not provided
- Amount of vehicle: 5 mL/kg bw - Analytical verification of doses or concentrations:
- no
- Details on analytical verification of doses or concentrations:
- not applicable
- Duration of treatment / exposure:
- 90 days
- Frequency of treatment:
- once daily
Doses / concentrationsopen allclose all
- Dose / conc.:
- 2 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 8 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 32 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- 10
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- 10 animals per sex were administered 0, 2, 8 and 32 mg/kg bw/day for 90 consecutive days. A satellite high dose group (32 mg/kg bw/day) and a satellite control group were also included and observed for 14 days after treatment.
- Dose selection rationale: Doses were selected according to the results of acute oral toxicity and repeated dose 28-day oral toxicity study.
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: not specified
- Cage side observations checked: mortality, moribund condition and clinical signs of toxicity
DETAILED CLINICAL OBSERVATIONS: No
BODY WEIGHT: Yes
- Time schedule for examinations: weekly
FOOD CONSUMPTION AND COMPOUND INTAKE: No
WATER CONSUMPTION AND COMPOUND INTAKE: No
FOOD EFFICIENCY: Yes
- The method of calculation was not specified.
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes
- Time schedule for collection of blood: at the end of treatment
- Anaesthetic used for blood collection: not specified
- Animals fasted: not specified
- How many animals: in all the treatment and control groups
- Parameters checked: haemoglobin (Hb), red blood cell count (RBC), differential white blood cell count (WBC), platelate count (PLT), plasma prothrombin time (PT) and activated partial thromboplatin (APTT).
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: at the end of treatment period
- Animals fasted: not specified
- How many animals: in all the treatment and control groups
- Parameters checked: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), total cholesterol (CHOL), total bilirubin (TBIL), glucose (GLU), blood urea nitrogen (BUN), creatinine (CREA), cholesterase (CHE), total protein (TP), albumin (ALB), sodium, potassium, chloride, calcium and phosphorous.
PLASMA/SERUM HORMONES/LIPIDS: No
URINALYSIS: Yes
- Time schedule for collection of urine: at the end of the treatment period
- Metabolism cages used for collection of urine: not specified
- Animals fasted: not specified
- Parameters checked: specific gravity, color, pH, protein contents, blood/blood cells and glucose concentration.
NEUROBEHAVIOURAL EXAMINATION: No
IMMUNOLOGY: No - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
All rats were subjected to gross necropsy and macroscopic examination at the end of the study period.
The following organs and tissues were weighed: brain, heart, lung, liver, spleen, kidney, adrenal gland, testis or ovary and thymus.
HISTOPATHOLOGY: Yes
The following tissues were fixed with 10% formaldehyde and sampled for histopathology: brain, heart, lung, liver, thymus, spleen, kidney, adrenal gland, testis or ovary, nervus ischiadicus, cervical, spinal cord, thyroid, pancreas, stomach, duodenum, jejunum, ileum, colon, rectum, mesenteric lymph node, prostate, epididymides, urinary bladder and uterus. - Statistics:
- Data was analyzed by ANOVA, and the additional high and control dose group were analyzed by t-test.
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Main groups:
Control: No clinical signs were observed.
2 mg/kg bw/day: No clinical signs were observed.
8 mg/kg bw/day: No clinical signs were observed.
32 mg/kg bw/day: fluffy hair (10/10 females and 10/10 males), slow breathing (5/10 females and 5/10 males), arched back (5/10 females and 5/10 males), lethargic (10/10 females and 10/10 males), delayed reaction (5/10 females and 5/10 males) and salivation (10/10 females and 10/10 males).
Satellite groups:
Control: No clinical signs were observed.
32 mg/kg bw/day: fluffy hair (10/10 females and 10/10 males), slow breathing (1/10 females and 3/10 males), arched back (1/10 females and 3/10 males), lethargic (10/10 females and 10/10 males), retard reaction (1/10 females and 3/10 males) and salivation (10/10 females and 10/10 males)
For details, please refer to the attached background material 1. - Mortality:
- no mortality observed
- Description (incidence):
- No deaths were observed during the treatment.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Main groups:
The body weight of the females given 32 mg/kg bw/day was statistically significantly reduced during Weeks 5 to 10 and during Week 12 compared to the control animals (maximum of -12%) whereas the body weight of the male animals treated with 32 mg/kg bw/day was statistically significantly reduced from Week 1 to 13 compared to the control group (maximum -25%). This reduction in body weight at 32 mg/kg bw/day is considered toxicollogically relevant. A statistically significant reduction of body weight was also observed in males treated with 8 mg/kg bw/day during Weeks 1 and 2 (approximately -7%) when compared to the control animal. This effect is not considered toxicologically relevant as the reduction in body weight was less than 10%. No statistically significant changes in body weight were observed for males given 2 mg/kg bw/day of the test substance and for females treated with 2 or 8 mg/kg bw/day compared to the controls. For all animals body weight gain was observed throughout the study period.
Satellite groups:
Similar to the above-mentioned observation, the body weight of the satellite animals treated with the high dose of the test substance (32 mg/kg bw/day) was statistically significantly reduced for both sexes. In male rats, the reduction in body weights was statistically significant during the whole study duration (Weeks 1 - 15, maximum of -20%) compared to the control group. In females, statistically significantly reduced body weights were observed during Week 1 to 11 and during Week 13 (maximum of -11%) when compared to the control animals. For all animals in the satellite groups, body weight gain was observed throughout the study period.
For details, please refer to the attached background material 2. - Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- no effects observed
- Description (incidence and severity):
- There were no changes regarding the food efficiency in male and female rats during the study.
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- No treatment-related effects were observed in any treatment group (main and satellite groups). In males of the satellite group treated with 32 mg/kg bw/day, there was a statistically significant increase in basophiles compared to the control. As the increase of basophils was minor and showed no dose-dependency, the effect was not considered treatment-related.
- Clinical biochemistry findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Main groups:
Biochemical detection of blood exhibited that TP was significantly decreased in the high and middle dose groups of male rats, and calcium ions was significantly increased in the middle dose groups of male rats compared to the control animals.
Satellite groups:
TBIL and calcium ions of female rats in the satellite high dose group were increased, while in male rats AST and ALP were increased compared to the additional control group.
All changes were not considered treatment-related, as the effects were only transient or where only observed in the satellite group and in one sex. - Endocrine findings:
- not examined
- Urinalysis findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Main groups:
No treatment-related urinary findings were observed in female rats. The urine of male rats (1/10) treated with 2, 8 and 32 mg/kg bw/day was protein positive. Since only one male animal was affected in each dose group, this effect was considered incidental and not related to the treatment with the test substance.
Satellite groups:
No treatment-related findings were observed in the animals during the study. - Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Main groups:
The absolute organ weights of brain, lung and kidney of the high dose group of female rats were statistically significantly decreased, whereas the relative heart weight was statistically significantly increased in the middle dose group of female rats compared to the control group.
For male rats, the absolute weights of heart, kidney and thymus were statistically significantly reduced in the high dose group, whereas the absolute lung weight was statistically significantly increased in the middle dose group. The relative weights of the brain, heart, lung, adrenal gland, and testis in the high dose group and the relative lung weight of the middle dose group were statistically significantly increased compared to the control.
Satellite groups:
The absolute and relative weight of the lung of female rats in the satellite group were statistically significantly increased. The relative brain and testis weight of male rats in the satellite group were significantly increased, but the absolute heart, liver, lung and kidney weights as well as the relative liver weight were statistically significantly decreased compared to the satellite control group.
All effects were considered not treatment-related, because the observed changes were opposite for absolute and relative organ weights, or occurred only in absolute weight, or were small (<20%), or were opposite for the main and satellite groups, or occurred only in one sex, or occurred differently in each sex, or were not accompanied by histopathological effects.
For details, please refer to the attached background material 1. - Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- No gross abnormalities were observed.
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Main groups:
Control: No histopathological findings were observed in female rats. In male rats incidental findings were observed including light-grade necrosis of myocardial cells (1/10), light-graded fatty degeneration of liver cells accompanied with light-grade infiltration of inflammatory cells (1/10), light-grade fatty degeneration of liver cells (1/10), light-grade of infiltration of inflammatory cells of prostate (2/10).
2 mg/kg bw/day: No treatment-related abnormalities were observed in males and females.
8 mg/kg bw/day: In females light-grade of proliferation of squamous epithelium of forestomach (3/10) was observed. In males light-grade lymphocyte necrosis of thymus (2/10) was observed.
32 mg/kg bw/day: In female rats isolated cases of light-grade consolidation of pulmonary aveoli (1/10), light-grade infiltration of inflammatory cells of gastric mucosa (1/10), light-grade infiltration of inflammatory cells of gastric mucosa of the forestomach (1/10), light-grade proliferation of squamous epithelium accompanied with light-grade infiltration of inflammatory cells of the forestomach (1/10), middle-grade proliferation of squamous epithelium of the forestomach (1/10), light-grade proliferation of squamous epithelium of the forestomach (1/10) and middle-grade proliferation of squamous epithelium accompanied with light-grade filtration of inflammatory cells of forestomach (1/10)
In male rats light-grade fatty degeneration of the liver cells (1/10), middle-grade lymphocyte necrosis of thymus (3/10), middle-grade proliferation of squamous epithelium of the forestomach (2/10), light-grade proliferation of squamous epithelium of the forestomach (1/10) and light-grade of infiltration of inflammatory cells of prostate (2/10) were observed.
Satellite groups:
Control: In females, no treatment-related abnormalities were observed. In males, observed histopathological findings included middle-grade fatty degeneration of liver cells (1/10), light-grade fatty degeneration of liver cells (1/10), middle-grade of infiltration of inflammatory cells of prostate (2/10), light-grade of infiltration of inflammatory cells of prostate (1/10) and light-grade of prostate epithelium (1/10).
32 mg/kg bw/day: In females, no treatment-related abnormalities were observed. In males, observed histopathological findings included light-grade fatty degeneration of the liver cells (1/10) and light-grade of infiltration of inflammatory cells of prostate (2/10).
Only the effects observed on the forestomach in the main groups are considered to be treatment-related, but reversibile as they were not observed in the satellite animals. - Histopathological findings: neoplastic:
- not examined
- Description (incidence and severity):
- Neoplastic changes were not examined.
- Other effects:
- not examined
- Description (incidence and severity):
- not applicable.
Effect levels
open allclose all
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- local
- Effect level:
- 2 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: No adverse effects were observed at this dose level.
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- systemic
- Effect level:
- 8 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: No adverse effects were observed at this dose level.
- Key result
- Dose descriptor:
- LOAEL
- Remarks:
- local
- Effect level:
- 8 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- histopathology: non-neoplastic
- Key result
- Dose descriptor:
- LOAEL
- Remarks:
- systemic
- Effect level:
- 32 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- body weight and weight gain
- clinical signs
Target system / organ toxicity
- Key result
- Critical effects observed:
- no
Applicant's summary and conclusion
- Conclusions:
- The present study was conducted to assess the effects of the test substance on rats when given for 90 days. The study was performed according to the guidelines for the testing of chemicals section 4: Health effects (Ministry of Environmental Protection of People's Republic of China) and similar to OECD TG 408 under non-GLP conditions. Rats received the test substance via gavage at doses of 2, 8 and 32 mg/kg bw/day. Under the conditions of the test, the test substance caused a reduction in body weight and clinical signs including fluffy fur, slow breathing, ached back, delayed reaction and salivation were observed in rats treated with 32 mg/kg bw/day. Local effects were observed in the forestomach (histopathology) in animals treated with 8 mg/kg bw/day. Therefore, the systemic NOAEL was set to 8 mg/kg bw/day, while the local NOAEL was set to 2 mg/kg bw/day.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.